The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Monitoring disease activity in multiple sclerosis using serum neurofilament light protein
Open accessAbstract
Objective: To examine the effects of disease activity, disability, and disease-modifying therapies (DMTs) on serum neurofilament light (NFL) and the correlation between NFL concentrations in serum and CSF in multiple sclerosis (MS). Methods: NFL concentrations were measured in paired serum and CSF samples (n = 521) from 373 participants: 286 had MS, 45 had other neurologic conditions, and 42 were healthy controls (HCs). In 138 patients with MS, the serum and CSF samples were obtained before and after DMT treatment with a median interval of 12 months. The CSF NFL concentration was measured with the UmanDiagnostics NF-light enzyme-linked immunosorbent assay. The serum NFL concentration was measured with an in-house ultrasensitive single-molecule array assay. Results: In MS, the correlation between serum and CSF NFL was r = 0.62 (p < 0.001). Serum concentrations were significantly higher in patients with relapsing-remitting MS (16.9 ng/L) and in patients with progressive MS (23 ng/L) than in HCs (10.5 ng/L, p < 0.001 and p < 0.001, respectively). Treatment with DMT reduced median serum NFL levels from 18.6 (interquartile range [IQR] 12.6–32.7) ng/L to 15.7 (IQR 9.6–22.7) ng/L (p < 0.001). Patients with relapse or with radiologic activity had significantly higher serum NFL levels than those in remission (p < 0.001) or those without new lesions on MRI (p < 0.001). Conclusions: Serum and CSF NFL levels were highly correlated, indicating that blood sampling can replace CSF taps for this particular marker. Disease activity and DMT had similar effects on serum and CSF NFL concentrations. Repeated NFL determinations in peripheral blood for detecting axonal damage may represent new possibilities in MS monitoring.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Exenatide has also exhibited the potential to lessen brain deterioration and disability in patients with MS. 87”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [87]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
McDonald, W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H., Lublin, F. D., McFarland, H. F., Paty, D. W., Polman, C. H., Reingold, S. C., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1032 · Cited by 6,969
Axonal transection in the lesions of multiple sclerosis
Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mörk, S., & Bö, L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380502 · Cited by 4,029
Rissin, D. M., Kan, C. W., Campbell, T. G., Howes, S. C., Fournier, D. R., Song, L., Piech, T., Patel, P. P., Chang, L., Rivnak, A. J., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1641 · Cited by 2,119
Multiple Sclerosis Severity Score: Using disability and disease duration to rate disease severity
Roxburgh, R. H. S. R., Seaman, S. R., Masterman, T., Hensiek, A. E., Sawcer, S. J., Vukusic, S., Achiti, I., Confavreux, C., Coustans, M., le Page, E., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000156155.19270.f8 · Cited by 963
A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking
Teunissen, C. E., Petzold, A., Bennett, J. L., Berven, F. S., Brundin, L., Comabella, M., Franciotta, D., Frederiksen, J. L., Fleming, J. O., Furlan, R., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c47cc2 · Cited by 845
Kuhle, J., Barro, C., Andreasson, U., Derfuss, T., Lindberg, R., Sandelius, Å., Liman, V., Norgren, N., Blennow, K., & Zetterberg, H. (2016) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2015-1195 · Cited by 740
Self-citationGisslén, M., Price, R. W., Andreasson, U., Norgren, N., Nilsson, S., Hagberg, L., Fuchs, D., Spudich, S., Blennow, K., & Zetterberg, H. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2015.11.036 · Cited by 481
Self-citationSerum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia
Rohrer, J. D., Woollacott, I. O. C., Dick, K. M., Brotherhood, E., Gordon, E., Fellows, A., Toombs, J., Druyeh, R., Cardoso, M. J., Ourselin, S., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000003154 · Cited by 432
Self-citationExploring the origins of grey matter damage in multiple sclerosis
Calabrese, M., Magliozzi, R., Ciccarelli, O., Geurts, J. J. G., Reynolds, R., & Martin, R. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3900 · Cited by 414
Cited by
Neurofilaments as biomarkers in neurological disorders
Khalil, M., Teunissen, C. E., Otto, M., Piehl, F., Sormani, M. P., Gattringer, T., Barro, C., Kappos, L., Comabella, M., Fazekas, F., et al. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0058-z · Cited by 1,988
Self-citationBenkert, P., Meier, S., Schaedelin, S., Manouchehrinia, A., Yaldizli, Ö., Maceski, A., Oechtering, J., Achtnichts, L., Conen, D., Derfuss, T., et al. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00009-6 · Cited by 628
Self-citationMultiple sclerosis: clinical aspects
Oh, J., Vidal-Jordana, A., & Montalban, X. (2018) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000622 · Cited by 620
Blood neurofilament light chain as a biomarker of MS disease activity and treatment response
Kuhle, J., Kropshofer, H., Haering, D. A., Kundu, U., Meinert, R., Barro, C., Dahlke, F., Tomic, D., Leppert, D., & Kappos, L. (2019) · Neurology · doi:10.1212/wnl.0000000000007032 · Cited by 568
A multicentre validation study of the diagnostic value of plasma neurofilament light.
Ashton, N. J., Janelidze, S., Al Khleifat, A., Leuzy, A., van der Ende, E. L., Karikari, T. K., Benedet, A. L., Pascoal, T. A., Lleó, A., Parnetti, L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23620-z · Cited by 545
Self-citation
Metadata
- Authors
- Novakova, L., Zetterberg, H., Sundström, P., Axelsson, M., Khademi, M., Gunnarsson, M., Malmeström, C., Svenningsson, A., Olsson, T., Piehl, F., Blennow, K., & Lycke, J.
- Affiliations
- Sahlgrenska University Hospital (SE)
- Corresponding author
- Novakova, Lenka
- ORCID
- Venue
- Neurology
- Published
- 2017-11-28
- Volume
- 89
- Issue
- 22
- Pages
- 2230-2237
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- PMC
- PMC5705244
- OpenAlex
- W2766371671
- Cited by
- 426
- References
- 32
- Citations by year
- 2026: 34 · 2025: 40 · 2024: 44 · 2023: 54 · 2022: 51 · 2021: 67 · 2020: 57 · 2019: 58 · 2018: 19 · 2017: 2
- FWCI
- 25.75
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Neurology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Eli Lilly and Company
- AstraZeneca
- Sanofi
- Biogen
- Teva Pharmaceutical Industries
- Association of Fraternity/Sorority Advisors Foundation
- Knut och Alice Wallenbergs Stiftelse
- Vetenskapsrådet
- Fujirebio Europe
- Göteborgs Universitet
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Health Sciences › Medicine › Clinical Neurology › Peripheral Neuropathies and Disorders
- Health Sciences › Medicine › Oncology › Polyomavirus and related diseases
- Keywords
- multiple sclerosis, cerebrospinal fluid biomarkers, disease activity, disease-modifying therapy, relapsing-remitting multiple sclerosis, progressive multiple sclerosis, axonal injury, disability, MRI lesion activity, blood-based biomarkers
- MeSH terms
- Adult, Aged, Disability Evaluation, Enzyme-Linked Immunosorbent Assay, Female, Follow-Up Studies, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Monitoring, Physiologic, Multiple Sclerosis, ROC Curve, Statistics as Topic, Sweden, Neurofilament Proteins, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. https://app.cochat.ai/papers/10.1212/wnl.0000000000004683
- The paper
- Novakova, L., Zetterberg, H., Sundström, P., Axelsson, M., Khademi, M., Gunnarsson, M., Malmeström, C., Svenningsson, A., Olsson, T., Piehl, F., Blennow, K., & Lycke, J. (2017). Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. Neurology. https://doi.org/10.1212/wnl.0000000000004683
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.